Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study

Απλή σελίδα τεκμηρίου
dc.contributor.authorGamucci, T.en
dc.contributor.authorParidaens, R.en
dc.contributor.authorHeinrich, B.en
dc.contributor.authorSchellens, J. H.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorVerweij, J.en
dc.contributor.authorSessa, C.en
dc.contributor.authorKaye, S.en
dc.contributor.authorRoelvink, M.en
dc.contributor.authorWanders, J.en
dc.contributor.authorHanauske, A.en
dc.date.accessioned2015-11-24T19:38:09Z
dc.date.available2015-11-24T19:38:09Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24116
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/adverse effects/*pharmacology/therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/pathologyen
dc.subjectCamptothecin/adverse effects/analogs & derivatives/*pharmacology/therapeutic useen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/pathologyen
dc.subjectColorectal Neoplasms/*drug therapy/pathologyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectLung Neoplasms/*drug therapy/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectTreatment Outcomeen
dc.titleActivity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical studyen
heal.abstractBACKGROUND: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. PATIENTS AND METHODS: Between April 1995 and November 1996, 67 eligible patients with pretreated breast cancer (25 patients) and chemo-naive colorectal (19 patients) and non-small-cell lung cancer (23 patients) were entered into three multicentric, non-randomized phase II trials. Treatment schedule consisted of intravenous GI1147211 administered at a dose of 1.2 mg/m2/day for five consecutive days every three weeks. RESULTS: Hematological toxicity was common with grade 3-4 neutropenia in 54% of patients and neutropenic fever together or not associated with infection in 14.5% of patients. Grade 3-4 thrombocytopenia and grade 2-4 anemia were observed in 20% and in 68% of patients, respectively. Non-hematological toxicity was generally mild to moderate and consisted mainly of gastrointestinal toxicity, asthenia and alopecia. A dose-escalation to 1.5 mg/m2/d was feasible in 17 (25%) patients. The antitumor activity of GI1147211 was moderate in breast cancer patients (3 partial responses (PRs), response rate (RR) 13%) and minimal in non-small cell lung cancer patients (2 PRs, RR 9%). No objective responses were obtained in colorectal patients. CONCLUSIONS: GI147211, at the dose and schedule employed in this study, showed an acceptable safety profile but a modest antitumor activity in the examined tumor types.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10997805-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/11/7/793.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ